Department of Internal Medicine, Division Vascular Medicine, Erasmus MC, 's-Gravendijkwal 230, 3015 CE, Rotterdam, the Netherlands.
Department of Cardiology, Erasmus MC, 's-Gravendijkwal 230, 3015 CE, Rotterdam, the Netherlands.
Maturitas. 2021 Feb;144:1-3. doi: 10.1016/j.maturitas.2020.09.007. Epub 2020 Sep 28.
In the past decade, the leading international cardiology societies have released statements that emphasize the importance of sex-specific reporting of the findings of clinical trials in cardiovascular research. To find out whether this has led to improvement, we compared sex-specific reporting of efficacy and safety outcomes for trials of cardiovascular drug interventions presented at the major clinical trials sessions of the European Society of Cardiology (ESC), American Heart Association (AHA) and the American College of Cardiology (ACC) before and after publication of these statements. We found that sex-specific efficacy and safety outcomes of the most influential cardiovascular intervention trials are still not systematically presented.
在过去的十年中，国际领先的心脏病学会发表声明强调指出，心血管研究中临床试验结果的报告应该根据性别进行具体区分。为了了解这是否有所改善，我们比较了在这些声明发表之前和之后，在欧洲心脏病学会（ESC）、美国心脏协会（AHA）和美国心脏病学会（ACC）的主要临床试验会议上报告的心血管药物干预试验的疗效和安全性结局的性别特异性报告。我们发现，最有影响力的心血管干预试验的性别特异性疗效和安全性结局仍然没有系统地呈现。
